Caribou Biosciences (CRBU)
(Delayed Data from NSDQ)
$1.69 USD
-0.09 (-5.06%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.70 +0.01 (0.59%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
11/05/2025
Time: -- |
9/2025 | $-0.35 | 0.00% |
Earnings Summary
For their last quarter, Caribou Biosciences (CRBU) reported earnings of -$0.35 per share, beating the Zacks Consensus Estimate of $-0.40 per share. This reflects a positive earnings surprise of 12.50%. Look out for CRBU's next earnings release expected on November 05, 2025. For the next earning release, we expect the company to report earnings of -$0.35 per share, reflecting a year-over-year increase of 7.89%.
Earnings History
Price & Consensus
Zacks News for CRBU
Caribou Biosciences (CRBU) Upgraded to Buy: Here's What You Should Know
CRBU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know
Will Caribou Biosciences, Inc. (CRBU) Report Negative Q1 Earnings? What You Should Know
CRBU FAQs
Based on past history, Zacks believes Caribou Biosciences, Inc. (CRBU) will report their next quarter earnings on November 05, 2025. For the next earning release, we expect the company to report earnings of -0.35 per share, reflecting a year-over-year increase of 7.89.
Based on past history, Zacks believes Caribou Biosciences, Inc. (CRBU) will report their previous quarter earnings %%TIME_OF_DAY_CODE%% on November 05, 2025.
The Zacks Consensus Estimate for Caribou Biosciences, Inc. (CRBU) for the quarter ending September 2025 is $-0.35 a share. We expect Caribou Biosciences, Inc. (CRBU) to report earnings in line with the consensus estimate of $-0.35 per share
In the earnings report for the quarter ending in June 2024, Caribou Biosciences, Inc. (CRBU) announced earnings of $-0.42 per share versus the Zacks Consensus Estimate of $-0.45 per share, representing a surprise of -6.67%.